Sections
- Alternative Medicine
- Childrens Health
- Dental Health
- Diseases and Conditions
- Fitness
- General Health
- Health Sciences
- Hospitals and Medical Centers
- Medical Technology
- Mens Health
- Mental Health
- Pharma and Biotech
- Procedures and Therapies
- Public Health and Safety
- Reproductive Health
- Senior Health
- Sexual Health
- Skin and Hair
- Women's Health
Pharma and Biotech
STELARA™ (Ustekinumab) Receives FDA Approval For Treatment Of Moderate To Severe Plaque Psoriasis With Four-Times-A-Year Maintenance Dosing
First-in-Class Anti-IL-12/23 Biologic Targets Proteins Believed to Play a Role in Psoriasis
Vical Presents Positive Preclinical Results with Vaxfectin(R)-Formulated, Peptide-based Cancer Vaccine
BOSTON, Sept. 24, 2009 -- Vical Incorporated (Nasdaq:VICL) announced today the presentation of encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company's Vaxfectin(R) adjuvant. Sean M. Sullivan, Ph.D., Vical's Executive Director of Pharmaceutical Sciences, is presenting data at the IIRUSA Vaccines Development Forum (Boston - September 23-25) demonstrating the adjuvant's ability to enhance immune responses of cancer antigen-based vaccines in addition to a broad variety of DNA- and protein-based vaccines against infectious diseases. ...Initial COIN Study Results Presented at European Oncology Congress
* Results inconsistent with data from all Erbitux pivotal studies * Further analyses planned by the Medical Research Council that conducted the independent COIN study ...Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer’s AROMASIN® (Exemestane Tablets)
91-Month Follow-up of the Intergroup Exemestane Study (IES) Demonstrated a Significant Disease-Free Survival Benefit in Favor of Switching to AROMASIN After 2 to 3 Years of Tamoxifen Compared to Continuing on Tamoxifen for 5 Years in Oestrogen-Receptor Positive/Unknown Postmenopausal Early Breast Cancer Patients ...Drug Discovery Process More Accurate, Less Expensive Using Novel Application
Cincinnati—Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts....Abbott's XIENCE V® Continues to Outperform TAXUS with Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
— Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major Adverse Cardiac Events (MACE) at Three Years and a 43 Percent Reduction vs. TAXUS — No Additional Stent Thrombosis between Two and Three Years, and Impressive Low Rate of Very Late Stent Thrombosis for XIENCE V ...Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
- Valturna combines in a single pill valsartan, an angiotensin receptor blocker, with aliskiren, the only approved direct renin inhibitor - Valturna is the first therapy to target two points within the renin angiotensin aldosterone system (RAAS), which plays a key role in regulating blood pressure - Valturna offers significantly greater blood pressure reduction than either valsartan or aliskiren alone[1]...Positive Phase IIb Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Post-Herpetic Neuralgia
RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.-- GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults....Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
South San Francisco, Calif. and Cambridge, Mass. -- Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Biogen Idec (Nasdaq: BIIB), today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan. ...Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis. ...Log in
- FDA Issues Early Communication about Ongoing Safety Review of Weight Loss Drug Orlistat
- Could standard treatment for traumatic brain injury be wrong?
- Scientists Take Early Steps Toward Mapping Epigenetic Variability
- Scientists discover a new way to kill cancer
- Site for alcohol's action in the brain discovered
- Study reveals major genetic differences between blood and tissue cells
- McGill/JGH researchers successfully reverse multiple sclerosis in animals
- Vitamin D, curcumin may help clear amyloid plaques found in Alzheimer's
- An HIV-Blocking Gel for Women
- Evidence of direct link between mutated gene and autism, York U study finds
- Vitamin D deficiency is widespread and on the increase
- Study reveals major genetic differences between blood and tissue cells
- Breast Cancer Survivors Who Receive Lymphedema Education Are More Likely to Have Fewer Symptoms
- Scientists identify cells in fruit fly gut that start tumors
- Remembering what to remember and what to forget
Gerc
on
07 September, 2009 01:56:27
Very, very interesting
Prof. dr. V. Gerc
Gerc
on
07 September, 2009 01:54:54
Very, very ineteresting.
Prof. dr. V. Gerc
Carole Martz
on
26 August, 2009 08:23:24
Congratulations Nurse Fu and Dr Axelrod on publishing this important study. Thank you for validating what I always knew. Preoperative nursing education regarding lymphedema risk ...
Gary McCallister
on
24 August, 2009 07:38:24
This doesn't change much of anything about how we treat patients and alleviate symptoms. All it dos is describe the parasite at a different ...
Doris Coward
on
23 August, 2009 12:53:08
Where can I find the full report of this study?
Thank you.
